Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 15 May 2018 |
| Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma | 8 May 2018 |
| Interim Report First Quarter 2018 | 8 May 2018 |
| Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting | 25 Apr 2018 |
| Genmab A/S has published its Articles of Association | 19 Apr 2018 |